Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | EED | O75530 | 3/20 | 0.30 |
| ▸ | SUZ12 | Q15022 | 3/20 | 0.30 |
| ▸ | EZH2 | Q15910 | 3/20 | 0.30 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2018098 | 0.74 | MAP3K14 (0.34) | MAP3K14 | |
| SCHEMBL2018101 | 0.74 | MAP3K14 (0.34) | MAP3K14 | |
| SCHEMBL11666222 | 0.67 | HTR2A (0.45) | HTR2AENPP2MAOAMAOB | |
| SCHEMBL5019354 | 0.66 | HTR2A (0.50) | HTR2AENPP2LRRK2MAOAMAOB | |
| SCHEMBL31595597 | 0.66 | HTR2A (0.50) | HTR2AENPP2LRRK2MAOAMAOB | |
| SCHEMBL7857614 | 0.64 | HTR2A (0.51) | HTR2AENPP2LRRK2TRPV1MAPK1 | |
| Hydrochloric Acid SCHEMBL11644062 | 0.64 | ENPP2 (0.42) | HTR2AENPP2LRRK2MAOAMAOB | |
| SCHEMBL2015637 | 0.63 | KDM4E (0.44) | MAPK1KDM4E | |
| SCHEMBL12574544 | 0.63 | MAP3K14 (0.35) | MAP3K14TRPV1 | |
| SCHEMBL2026135 | 0.63 | MAP3K14 (0.35) | MAP3K14TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338591-B2 | 3-aryl-5,6-disubstituted pyridazines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-12-25 | — | — | US | disclosed |
| US-20110160187-A1 | 3-aryl-5,6-disubstituted pyridazines | NEUROGEN CORPORATION (US) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160187-A1 | 3-aryl-5,6-disubstituted pyridazines | MMP25, MMP9, MMP3 | HTR2A 2175/4885ENPP2 175/4885MAP3K14 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.